597 results on '"Carroll, Miles W"'
Search Results
2. Serological evidence of zoonotic filovirus exposure among bushmeat hunters in Guinea
3. The P323L substitution in the SARS-CoV-2 polymerase (NSP12) confers a selective advantage during infection
4. Serum HCoV-spike specific antibodies do not protect against subsequent SARS-CoV-2 infection in children and adolescents
5. Influence of Landscape Patterns on Exposure to Lassa Fever Virus, Guinea
6. Mammalian expression systems and vaccination
7. Identification of novel antiviral drug candidates using an optimized SARS-CoV-2 phenotypic screening platform
8. Divergent trajectories of antiviral memory after SARS-CoV-2 infection
9. Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial
10. Nipah Virus Therapeutics: A Systematic Review to Support Prioritisation for Clinical Trials
11. Resurgence of Ebola virus in 2021 in Guinea suggests a new paradigm for outbreaks
12. Longitudinal antibody and T cell responses in Ebola virus disease survivors and contacts: an observational cohort study
13. Virus genomes reveal factors that spread and sustained the Ebola epidemic
14. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial
15. Human Diversity of Killer Cell Immunoglobulin-Like Receptors and Human Leukocyte Antigen Class I Alleles and Ebola Virus Disease Outcomes
16. Rvsv-Zebov Vaccination in People with Pre-Existing Immunity to Ebolavirus: An Open-Label Safety and Immunogenicity Study in Guinean Communities Affected by Ebola Virus Disease (L’Essai Proches)
17. A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses
18. Analysis of an Ebola virus disease survivor whose host and viral markers were predictive of death indicates the effectiveness of medical countermeasures and supportive care
19. Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19
20. A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19
21. ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models
22. Severity of heterosubtypic influenza virus infection in ferrets is reduced by live attenuated influenza vaccine
23. Dose-dependent response to infection with SARS-CoV-2 in the ferret model and evidence of protective immunity
24. Animal models for COVID-19
25. Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient
26. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2
27. Early transmission and case fatality of Ebola virus at the index site of the 2013–16 west African Ebola outbreak: a cross-sectional seroprevalence survey
28. Pseudotyping of VSV with Ebola virus glycoprotein is superior to HIV-1 for the assessment of neutralising antibodies
29. Development of immunohistochemistry and in situ hybridisation for the detection of SARS-CoV and SARS-CoV-2 in formalin-fixed paraffin-embedded specimens
30. Case study: design and implementation of training for scientists deploying to Ebola diagnostic field laboratories in Sierra Leone: October 2014 to February 2016
31. Ebola Virus Persistence in Breast Milk After No Reported Illness: A Likely Source of Virus Transmission From Mother to Child
32. Gonadal androgens are associated with decreased type I interferon production by pDCs and increased IgG titres to BNT162b2 following co-vaccination with live attenuated influenza vaccine in adolescents
33. Development of vaccines against Crimean-Congo haemorrhagic fever virus
34. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)
35. Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors: a longitudinal analysis and modelling study
36. Variation around the dominant viral genome sequence contributes to viral load and outcome in patients with Ebola virus disease
37. A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction
38. Characterisation of the transcriptome and proteome of SARS-CoV-2 reveals a cell passage induced in-frame deletion of the furin-like cleavage site from the spike glycoprotein
39. Immunogenicity of a DNA vaccine candidate for COVID-19
40. Vaccination with a Recombinant Vaccinia Virus Encoding a "self" Antigen Induces Autoimmune Vitiligo and Tumor Cell Destruction in Mice: Requirement for Cd4 + T Lymphocytes
41. Recombinant Modified Vaccinia Virus Ankara-Simian Immunodeficiency Virus gag pol Elicits Cytotoxic T Lymphocytes in Rhesus Monkeys Detected by a Major Histocompatibility Complex Class I/Peptide Tetramer
42. Pre-clinical models to define correlates of protection for SARS-CoV-2
43. Antigen Expression by Dendritic Cells Correlates with the Therapeutic Effectiveness of a Model Recombinant Poxvirus Tumor Vaccine
44. Resurgence of Ebola Virus Disease in Guinea Linked to a Survivor With Virus Persistence in Seminal Fluid for More Than 500 Days
45. Analysis of Diagnostic Findings From the European Mobile Laboratory in Guéckédou, Guinea, March 2014 Through March 2015
46. Development of a Cost-effective Ovine Polyclonal Antibody-Based Product, EBOTAb, to Treat Ebola Virus Infection
47. Author Correction: Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2
48. Heterosubtypic cross-protection correlates with cross-reactive interferon-gamma-secreting lymphocytes in the ferret model of influenza
49. Alkyne Derivatives of SARS-CoV-2 Main Protease Inhibitors Including Nirmatrelvir Inhibit by Reacting Covalently with the Nucleophilic Cysteine
50. Quantifying human-animal contact rates in Malaysian Borneo: Influence of agricultural landscapes on contact with potential zoonotic disease reservoirs
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.